申请人:Takeda San Diego, Inc.
公开号:EP2133349A1
公开(公告)日:2009-12-16
The invention provides a compound of formula:
or a pharmaceutically acceptable salt, biohydrolysable ester, biohydrolysable amide, biohydrolysable carbamate, solvate or hydrate thereof, wherein R1, R2, R4, R5, R6, R7, Y3 and R14 have the meanings given in the specification. The compounds are kinase inhibitors and are useful in treating a number of disorders, including cancer, inflammation, dementia related diseases and arthritis.
本发明提供了一种式化合物:或其药学上可接受的盐、生物可水解酯、生物可水解酰胺、生物可水解氨基甲酸酯、溶液或水合物,其中 R1、R2、R4、R5、R6、R7、Y3 和 R14 具有说明书中给出的含义。 这些化合物是激酶抑制剂,可用于治疗多种疾病,包括癌症、炎症、痴呆相关疾病和关节炎。